Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Exosome Diagnostics
MedTech
Bio-Techne nets FDA breakthrough ticket for prostate cancer test
Bio-Techne’s urine test has received a breakthrough device designation from the FDA for ruling out unnecessary tissue biopsies.
Conor Hale
Jun 19, 2019 10:33am
Bio-Techne to pay up to $575M for Exosome Diagnostics
Jun 27, 2018 9:35am
CareFirst, Myriad Genetics ally to trial rheumatoid arthritis test
Nov 6, 2017 10:26am
Exosome, CareFirst partner to speed up coverage for diagnostic tests
Aug 25, 2017 11:30am
Exosome Diagnostics teams with Amgen for liquid biopsy test development
Oct 3, 2016 8:50am
